trending Market Intelligence /marketintelligence/en/news-insights/trending/RDkdKKz4MmZKH_nWGSYhGw2 content esgSubNav
In This List

Abbott's heart implant devices for children wins EU approval

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Abbott's heart implant devices for children wins EU approval

Abbott Laboratories said its Masters HP and Amplatzer Piccolo Occluder devices were approved in the EU to treat babies and children born with certain common inherited heart defects.

The Abbott Park, Ill.-based medical-device maker said the Masters valve is a small mechanical heart valve that treats babies in need of a mitral or aortic heart valve replacement. Amplatzer Piccolo is a medical device that can be implanted in babies to treat patent ductus arteriosus — a persistent opening between the two major blood vessels leading from the heart.

Abbott noted in its Sept. 17 press release that congenital heart defects affect about 36,000 births in the EU each year. The two devices are already available in the U.S.